Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Fernández Santander, Ana ^a   Gaibar, María ^a   Novillo, Apolonia ^a   Romero Lorca, Alicia ^a   Rubio, Margarita ^a   Chicharro, Luis Miguel ^a   Tejerina, Armando ^a   Bandrés, Fernando ^a  

^a UNIVERSIDAD EUROPEA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; ENDOXIFEN; NORTAMOXIFEN; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A2; TAMOXIFEN; TAMOXIFEN DERIVATIVE; TAMOXIFEN N OXIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CYP2D6 GENE; CYP3A4 GENE; CYP3A5 GENE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME SUBSTRATE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; PHARMACOGENETICS; SULT1A1 GENE; SULT1A2 GENE; SULT1E1 GENE; TANDEM MASS SPECTROMETRY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS, HORMONAL; ARYLSULFOTRANSFERASE; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PHARMACOGENETICS; TAMOXIFEN;

EID: 84880782733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070183     Document Type: Article

References (49)

1. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, et al. (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Ins 88: 1529-1542.
2. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, et al. (2004) Pharmacological characterization of 4-hydroxy- N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85(2): 151-159.
3. Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, et al. (2005) Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients. 28th Annual San Antonio Breast Cancer Symposium Dec 08-11; San Antonio, TX.
4. Tan SH, Lee SC, Goh BC, Wong J, (2008) Pharmacogenetics in Breast Cancer Therapy. Clin Cancer Res 24: 8027-8041.
5. Hildebrandt M, Adjei A, Weinshilboum R, Johnson JA, Berlin DS, et al. (2009) Very important pharmacogene summary: sulfotransferase 1A1. Pharmacogenet Genomics 19: 404-406.
6. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, et al. (2005) Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91: 249-258.
7. Desta Z, Ward BA, Soukhova NV, Flockhart DA, (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310: 1062-1075.
8. Sim SC, Ingelman-Sundberg M, (2010) The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics 4(4): 278-81 (The Human Cytochrome P450 (CYP) Allele Nomenclature Database web site. Available: http://www.cypalleles.ki.se/. Accessed 2013 Mar 14).
9. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, et al. (2007) CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 17(2): 93-101.
10. Fernández-Santander A, del Saz M, Tejerina A, Bandrés F, (2012) CYP2D6*4 allele and breast cancer risk: is there any association? Clin Transl Oncol 14(2): 157-159.
11. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27: 383-91.
12. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11: 773-9.
13. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J, (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48: 1668-71.
14. King BP, Leathart JB, Mutch E, Williams FM, Daly AK, (2003) CYP3A5 phenotype genotype correlations in a British population. Br J Clin Pharmacol 55: 625-9.
15. Lee SJ, Goldstein JA, (2005) Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 6: 357-71.
16. van Schaik RHN, de Wildt SN, Brosens R, van Fessem M, van den Anker JN, et al. (2001) CYP3A4*3 Allele: Is It Really Rare? Clin Chem 47(6): 1104-1106.
17. Chu W, Fyles A, Sellers EM, McCready DR, Murphy J, et al. (2007) Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis 28(10): 2139-42.
18. Mugundu GM, Sallans L, Guo Y, Shaughnessy EA, Desai PB, (2011) Assessment of the impact of polymorphisms of CYP3A on the formation of α-hydroxy tamoxifen and N-desmethyl tamoxifen in human liver microsomes. Drug Metabol Dispos 40(2): 389-96.
19. Lim YC, Desta Z, Flockhart DA, Skaar T, (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55: 471-478.
20. Falany JL, Macrina N, Falany CN, (2002) Regulation of MCF-7 breast cancer cell growth by h-estradiol sulfation. Breast Cancer Res Treat 74: 167-76.
21. Falany JL, Falany CN, (1996) Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Res 56: 1551-5.
22. Choi JY, Lee KM, Park SK, Noh DY, Ahn SH, et al. (2005) Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev 14: 1090-1095.
23. Dunn BK, Greene MH, Kelley JM, Costantino JP, Clifford RJ, et al. (2010) Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial. Int J Mol Epidemiol Genet 1(4): 332-49.
24. Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, et al. (2002) The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics. 12(5): 355-66.
25. Salameh G, Al Hadidi K, El Khateeb M, (2012) Genetic polymorphisms of the CYP3A4, CYP3A5, CYP3A7 and CYP1A2 among the Jordanian population. Environ Toxicol Pharmacol 34(1): 23-33.
26. Coughtrie MW, Gilissen RA, Shek B, Strange RC, Fryer AA, et al. (1999) Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J 337: 45-49.
27. Arslan S, (2010) Genetic polymorphisms of sulfotransferases (SULT1A1 and SULT1A2) in a Turkish population. Biochem Genet 48(11-12): 987-94.
28. Adjei AA, Thomae BA, Prondzinski JL, Eckloff BW, Wieben ED, et al. (2003) Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics. Br J Pharmacol 139(8): 1373-1382.
29. Scordo MG, Caputi PA, D'Arrigo C, Fava G, Spina E, (2004) Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 50: 195-200.
30. Ingelman-Sundberg M, (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5(1): 6-13.
31. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, et al. (2007) Genetic polymorphisms of drug-metabolising enzymes CYP2D6, CYP2C9, CYP2C19, and CYP3A5 in the Geek population. Fundament Clin Pharmacol 21: 419-26.
32. Oliveira E, Marsh S, van Booven DJ, Amorim A, Prata MJ, et al. (2007) Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics 8: 703-12.
33. Keshava C, McCanlies EC, Weston A, (2004) CYP3A4 Polymorphisms-Potential Risk Factors for Breast and Prostate Cancer: A HuGE Review. Am J Epidemiol 160: 825-841.
34. Kim KA, Lee SY, Park PW, Ha JM, Park JY, (2005) Genetic polymorphisms and linkage disequilibrium of sulfotransferase SULT1A1 and SULT1A2 in a Korean population: comparison of other ethnic groups. Eur J Clin Pharmacol 61(10): 743-747.
35. Borges S, Desta Z, Li L, Skaar TC, Ward BA, (2005) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80(1): 61-74.
36. Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR, (2003) Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J. Chromatogr B Analyt Technol Biomed Life Sci 791: 245-253.
37. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, et al. (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95: 1758-64.
38. Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, et al. (2011) Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma. Clin Pharmacol Ther 89(5): 708-17.
39. Jin Y, Desta Z, Stearns V, Ward B, Ho H, et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97(1): 30-9.
40. Lim HS, Lee HJ, Lee KS, Lee ES, Jang IJ, et al. (2007) Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 25(25): 3837-45.
41. Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, et al. (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28(8): 1287-93.
42. Fleeman N, Martin Saborido C, Payne K, Boland A, Dickson R, et al. (2011) The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. Health Technol Assess 15(33): 1-102.
43. Damodaran SE, Pradhan SC, Umamaheswaran G, Kadambari D, Reddy KS, (2012) Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. Cancer Chemother Pharmacol 70(1): 75-81.
44. Kiyotani K, Mushiroda T, Nakamura Y, Zembutsu H, (2011) Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab Pharmacokinet 27(1): 122-31.
45. Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, et al. (2008) Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19: 56-61.
46. Nowell S, Sweeney C, Winters M, Stone A, Lang NP, et al. (2002) Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 94: 1635-40.
47. Gjerde J, Geisler J, Lundgren S, Ekse D, Varhaug JE, et al. (2010) Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 21: 10-313.
48. Falany JL, Pilloff DE, Leyh TS, Falany CN, (2006) Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases. Drug Metab Dispos 34(3): 361-8.
49. Glatt H, Meinl W, (2004) Pharmacogenetics of soluble sulfotransferases (SULTs). Naunyn Schmiedebergs Arch Pharmacol 369(1): 55-68.